Celldex Therapeutics, Inc. (CLDX)
27.53
-1.40
(-4.84%)
USD |
NASDAQ |
Oct 16, 16:00
27.53
0.00 (0.00%)
After-Hours: 18:28
Celldex Therapeutics Net Income (Quarterly) : -73.50M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -73.50M |
| March 31, 2026 | -78.68M |
| December 31, 2025 | -81.32M |
| September 30, 2025 | -67.04M |
| June 30, 2025 | -56.60M |
| March 31, 2025 | -53.80M |
| December 31, 2024 | -47.09M |
| September 30, 2024 | -42.12M |
| June 30, 2024 | -35.84M |
| March 31, 2024 | -32.81M |
| December 31, 2023 | -43.31M |
| September 30, 2023 | -38.26M |
| June 30, 2023 | -30.50M |
| March 31, 2023 | -29.36M |
| December 31, 2022 | -26.49M |
| September 30, 2022 | -26.78M |
| June 30, 2022 | -36.00M |
| March 31, 2022 | -23.05M |
| December 31, 2021 | -20.15M |
| September 30, 2021 | -20.45M |
| June 30, 2021 | -13.37M |
| March 31, 2021 | -16.54M |
| December 31, 2020 | -21.90M |
| September 30, 2020 | -14.22M |
| June 30, 2020 | -11.03M |
| Date | Value |
|---|---|
| March 31, 2020 | -12.62M |
| December 31, 2019 | -10.45M |
| September 30, 2019 | -11.41M |
| June 30, 2019 | -11.78M |
| March 31, 2019 | -17.24M |
| December 31, 2018 | -9.402M |
| September 30, 2018 | -7.243M |
| June 30, 2018 | -16.41M |
| March 31, 2018 | -118.13M |
| December 31, 2017 | -3.841M |
| September 30, 2017 | -26.36M |
| June 30, 2017 | -28.57M |
| March 31, 2017 | -34.26M |
| December 31, 2016 | -32.31M |
| September 30, 2016 | -29.60M |
| June 30, 2016 | -31.95M |
| March 31, 2016 | -34.67M |
| December 31, 2015 | -32.68M |
| September 30, 2015 | -31.98M |
| June 30, 2015 | -32.36M |
| March 31, 2015 | -30.17M |
| December 31, 2014 | -31.82M |
| September 30, 2014 | -28.08M |
| June 30, 2014 | -28.27M |
| March 31, 2014 | -29.90M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Gilead Sciences, Inc. | -10.50B |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.022M |
| Total Expenses (Quarterly) | 73.52M |
| EPS Diluted (Quarterly) | -0.9443 |
| Enterprise Value | 1.565B |
| Gross Profit Margin (Quarterly) | -4.00K% |
| Profit Margin (Quarterly) | -334.1K% |
| Earnings Yield | -15.83% |
| Normalized Earnings Yield | -15.83 |